A Phase 1/2 interventional study of X4P-001 and axitinib in Clear Cell Renal Cell Carcinoma, sponsored by X4 Pharmaceuticals. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by X4 Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.
Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 321st largest by enrollment of the 1,008 interventional ones that give a count, is one of 43 that started in 2016, is one of 146 in phase 1/2, and was the 614th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18–100 · Men only
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 488 · Phase 2 529 · Phase 3 74 · Phase 4 10
First in 1990; this study’s year is marked. 43 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 1,008 interventional studies, 100 across the 87 observational. Of the 791 that completed or were terminated, 336 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
467 of 1,142 have an industry lead sponsor. The 10 most frequent:
X4 Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
X4 Pharmaceuticals has 2 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
98 of the studies in Carcinoma, Renal Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT05863351Phase 3ECOG-ACRIN Cancer Research GroupFocused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | 2027-08-31 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.
X4P-001 is an orally bioavailable C-X-C chemokine receptor type 4 (CXCR4) antagonist that has demonstrated activity in various tumor models. CXCR4 is the receptor for C-X-C chemokine ligand type 12 (CXCL12). CXCL12 has potent chemotactic activity for lymphocytes and myeloid-derived suppressor cells (MDSCs), and is important in homing of hematopoietic stem cells to the bone marrow. CXCR4 is also expressed and active on multiple types of human cancers, including clear cell Renal Cell Carcinoma (ccRCC), ovarian cancer, and melanoma, and increased expression of CXCR4 on tumor cells has been associated with significantly decreased overall participant survival.
Multiple observations implicate the CXCL12/CXCR4 axis in contributing to the lack (or loss) of tumor responsiveness to angiogenesis inhibitors (also referred to as "angiogenic escape"). In animal cancer models, interference with CXCR4 function has been demonstrated to disrupt the tumor microenvironment and unmask the tumor to immune attack by multiple mechanisms, including:
The hypothesis and evidence of published data support is that effective CXCR4 antagonism by X4P-001 would be of potential benefit in participants with advanced ccRCC and other cancers by multiple mechanisms:
This initial clinical trial in participants with advanced ccRCC will evaluate X4P-001 both as a single agent (monotherapy) and also in combination with axitinib, a small molecule tyrosine kinase inhibitor (TKI) approved for second-line treatment of participants with ccRCC. This combination has the potential to further improve outcomes by reducing the angiogenic escape that typically occurs with TKI therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has a prior history or current evidence of intracranial (CNS) RCC, except for
≤3 lesions treated by CyberKnife or excisional surgery, clinically stable for at least 4 weeks, and without evidence of recurrence on MRI imaging at screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive X4P-001 200 milligrams (mg) orally twice daily (BID) with axitinib at 5 mg orally BID.
Drug: X4P-001 · Drug: axitinib
Participants will receive X4P-001 400 mg orally once daily (QD) with axitinib at 5 mg orally BID.
Drug: X4P-001 · Drug: axitinib
Participants will receive X4P-001 600 mg orally QD with axitinib at 5 mg orally BID.
Drug: X4P-001 · Drug: axitinib
Participants received X4P-001 400 mg orally QD with axitinib at 5 mg orally BID.
Drug: X4P-001 · Drug: axitinib
Participants will receive X4P-001 600 mg orally QD.
Drug: X4P-001
Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. Adverse events with onset after administration of the first dose of study drug up to 10 days after last dosing date were considered TEAEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: From first dose of study drug up to 10 days after last dosing (maximum exposure: 52.1 months)
Parts A and B: Objective Response Rate (ORR), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
The ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 millimeters (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From administration of first dose of study medication until disease progression, study completion or early termination (up to 80 weeks)
Parts A and B: Time to Objective Response, as Assessed Using RECIST v1.1
Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever came first. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From administration of first dose of study medication until first appearance of CR or PR (up to 80 weeks)
Parts A and B: Duration of Objective Response (DOR), as Assessed Using RECIST v1.1
The DOR was defined as the time from first CR or PR whichever came first until the time of disease progression or death by any cause. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.
Time frame: Time from first CR or PR until the time of disease progression or death due to any cause (up to 80 weeks)
Parts A and B: Disease Control Rate (DCR), as Assessed Using RECIST v1.1
The DCR was defined as the percentage of participants with best overall response of CR, PR or stable disease (SD). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.
Time frame: From administration of first dose of study medication until disease progression, study completion or early termination (up to 80 weeks)
Parts A and B: Time to Progression (TTP), as Assessed Using RECIST v1.1
The TTP was defined as the time from first administration of combination regimen until PD. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
Time frame: From administration of first dose of study medication until disease progression (up to 80 weeks)
Parts A and B: Progression Free Survival (PFS), as Assessed Using RECIST v1.1
The PFS was defined as the time from first administration of combination regimen until disease progression or death from any cause. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
Time frame: From administration of first dose of study medication until disease progression or death from any cause (up to 80 weeks)
Parts A and B: Maximum Plasma Concentration (Cmax) of X4P-001
Time frame: Day 1 and Day 15 of Cycle 1
Area Under the Curve From Time 0 to the Last Quantifiable Timepoint (AUC0-tlast)
Time frame: Day 1 and Day 15 of Cycle 1
| Milestone | Dose Escalation (Part A): X4P-001 200 mg BID With Axitinib | Dose Escalation (Part A): X4P-001 400 mg QD With Axitinib | Dose Escalation (Part A): X4P-001 600 mg QD With Axitinib | Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib | Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy |
|---|---|---|---|---|---|
| Started | 3 | 7 | 6 | 0 | 0 |
| Received at least 1 dose of study drug | 3 | 7 | 6 | 0 | 0 |
| Completed | 1 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 7 | 6 | 0 | 0 |
| Withdrew: Adverse event | 1 | 3 | 1 | 0 | 0 |
| Withdrew: Disease progression | 1 | 4 | 3 | 0 | 0 |
| Withdrew: Dose-limiting toxicity (dlt) | 0 | 0 | 2 | 0 | 0 |
| Milestone | Dose Escalation (Part A): X4P-001 200 mg BID With Axitinib | Dose Escalation (Part A): X4P-001 400 mg QD With Axitinib | Dose Escalation (Part A): X4P-001 600 mg QD With Axitinib | Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib | Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 55 | 0 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 55 | 0 |
| Completed | 0 | 0 | 0 | 1 | 0 |
| Not completed | 0 | 0 | 0 | 54 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 9 | 0 |
| Withdrew: Clinical deterioration | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 38 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 | 0 |
| Milestone | Dose Escalation (Part A): X4P-001 200 mg BID With Axitinib | Dose Escalation (Part A): X4P-001 400 mg QD With Axitinib | Dose Escalation (Part A): X4P-001 600 mg QD With Axitinib | Dose Expansion (Part B): X4P-001 400 mg QD With Axitinib | Dose Escalation and Expansion (Part C): X4P-001 600 mg QD Monotherapy |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 3 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 0 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Dlt | 0 | 0 | 0 | 0 | 2 |
An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. Adverse events with onset after administration of the first dose of study drug up to 10 days after last dosing date were considered TEAEs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib | X4P-001 600 mg QD Monotherapy |
|---|---|---|---|---|
| Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 3 | 62 | 6 | 3 |
The ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 millimeters (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib |
|---|---|---|
| Parts A and B: Objective Response Rate (ORR), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | 66.7 (9.4 to 99.2) | 27.1 (16.4 to 40.3) |
Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever came first. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib |
|---|---|---|
| Parts A and B: Time to Objective Response, as Assessed Using RECIST v1.1 | 12.9 (1.9 to NA) | 14.6 (12.9 to NA) |
The DOR was defined as the time from first CR or PR whichever came first until the time of disease progression or death by any cause. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.
| months | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib |
|---|---|---|
| Parts A and B: Duration of Objective Response (DOR), as Assessed Using RECIST v1.1 | NA (9.2 to NA) | 16.6 (10.8 to 36.0) |
The DCR was defined as the percentage of participants with best overall response of CR, PR or stable disease (SD). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.
| percentage of participants | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib |
|---|---|---|
| Parts A and B: Disease Control Rate (DCR), as Assessed Using RECIST v1.1 | 100.0 (29.2 to 100.0) | 71.2 (57.9 to 82.2) |
The TTP was defined as the time from first administration of combination regimen until PD. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
| months | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib |
|---|---|---|
| Parts A and B: Time to Progression (TTP), as Assessed Using RECIST v1.1 | 11.1 (5.5 to NA) | 7.4 (5.6 to 14.7) |
The PFS was defined as the time from first administration of combination regimen until disease progression or death from any cause. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.
| months | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib |
|---|---|---|
| Parts A and B: Progression Free Survival (PFS), as Assessed Using RECIST v1.1 | 11.1 (5.5 to NA) | 7.4 (5.5 to 12.5) |
| nanograms (ng)/milliliter (mL) | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib |
|---|---|---|---|
| Day 1 | 1070 ± 59.5 | 3130 ± 67.2 | 4170 ± 42.7 |
| Day 15 | 831 ± 8.20 | 3710 ± 73.5 | 3900 ± 39.2 |
| hours*ng/mL | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib |
|---|---|---|---|
| Day 1 | 2200 ± 62.8 | 6790 ± 80.2 | 9830 ± 54.3 |
| Day 15 | 3000 ± 26.4 | 13100 ± 90.7 | 15100 ± 44.3 |
Collected over From first dose of study drug up to 10 days after last dosing (maximum exposure: 52.1 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| X4P-001 200 mg BID With Axitinib | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| X4P-001 400 mg QD With Axitinib | 2/62 (3.2%) | 26/62 (41.9%) | 62/62 (100%) |
| X4P-001 600 mg QD With Axitinib | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| X4P-001 600 mg QD Monotherapy | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib | X4P-001 600 mg QD Monotherapy |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/3 | 0/62 | 0/6 | 0/3 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 0/62 | 1/6 | 1/3 |
| HyperglycemiaMetabolism and nutrition disorders | 0/3 | 0/62 | 0/6 | 1/3 |
| DiarrheaGastrointestinal disorders | 0/3 | 2/62 | 1/6 | 0/3 |
| PainGeneral disorders | 0/3 | 2/62 | 0/6 | 0/3 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/3 | 2/62 | 0/6 | 0/3 |
| HypertensionVascular disorders | 0/3 | 2/62 | 0/6 | 0/3 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/62 | 0/6 | 0/3 |
| Abdominal distensionGastrointestinal disorders | 0/3 | 1/62 | 0/6 | 0/3 |
| AscitesGastrointestinal disorders | 0/3 | 1/62 | 0/6 | 0/3 |
| Event | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib | X4P-001 600 mg QD Monotherapy |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/3 | 33/62 | 3/6 | 1/3 |
| FatigueGeneral disorders | 3/3 | 30/62 | 5/6 | 2/3 |
| Abnormal loss of weightMetabolism and nutrition disorders | 3/3 | 2/62 | 1/6 | 0/3 |
| HeadacheNervous system disorders | 3/3 | 13/62 | 1/6 | 0/3 |
| HypertensionVascular disorders | 3/3 | 24/62 | 3/6 | 0/3 |
| NauseaGastrointestinal disorders | 2/3 | 22/62 | 3/6 | 2/3 |
| VomitingGastrointestinal disorders | 2/3 | 20/62 | 1/6 | 0/3 |
| ConstipationGastrointestinal disorders | 2/3 | 12/62 | 0/6 | 2/3 |
| Weight decreasedInvestigations | 1/3 | 28/62 | 0/6 | 2/3 |
| Non-cardiac chest painGeneral disorders | 2/3 | 6/62 | 0/6 | 0/3 |
Safety population included all participants who received at least 1 dose of study drug. As planned, Baseline Characteristics data collected per dose level not per study part.
| Age, Customized(Participants) | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib | X4P-001 600 mg QD Monotherapy | Total |
|---|---|---|---|---|---|
| 16-64 Years | 3 | 37 | 4 | 1 | 45 |
| ≥65 Years | 0 | 25 | 2 | 2 | 29 |
| Sex: Female, Male(Participants) | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib | X4P-001 600 mg QD Monotherapy | Total |
|---|---|---|---|---|---|
| Female | 0 | 10 | 0 | 2 | 12 |
| Male | 3 | 52 | 6 | 1 | 62 |
| Ethnicity (NIH/OMB)(Participants) | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib | X4P-001 600 mg QD Monotherapy | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 7 | 0 | 0 | 7 |
| Not Hispanic or Latino | 3 | 55 | 6 | 3 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | X4P-001 200 mg BID With Axitinib | X4P-001 400 mg QD With Axitinib | X4P-001 600 mg QD With Axitinib | X4P-001 600 mg QD Monotherapy | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 17 | 0 | 0 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 0 | 2 |
| White | 3 | 40 | 6 | 3 | 52 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Apr 2022, 71 months.
Results were first posted in Aug 2024, 2 years 4 months after primary completion. A results delay was requested in Mar 2023.
Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 71 months is close to that.
Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mavorixafor
X4 Pharmaceuticals